ClinicalTrials.gg
RecruitingNCT07241039Updated Aug 19, 2026

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

A Phase 1 interventional study of ABBV-711 and Budigalimab in Advanced Squamous Tumors, sponsored by AbbVie. Recruiting at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Squamous Cell Carcinoma of Head and Neck by AbbVie — 5 open to participants now, 7 under way, none of them phase 3. Squamous Cell Carcinoma of Head and Neck · AbbVie.

Planned enrollment
4th of 14
220 · median 116
Started
2025
the only one that year
Phase 1
13 of 14
4 open now
Registered
12th of 14
by date

Among the 14 studies in Squamous Cell Carcinoma of Head and Neck by AbbVie, this one is the 4th largest by planned enrollment, is the only one that started in 2025, is one of 13 in phase 1, and was the 12th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

5 of the 14 studies in Squamous Cell Carcinoma of Head and Neck by AbbVie are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Squamous Cell Carcinoma of Head and Neck by AbbVie, or all of them as a file.
02

Study summary

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy and in combination with budigalimab (ABBV-181) in adults with advanced squamous tumors.

ABBV-711 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-711 as a single agent or in combination with budigalimab (another investigational drug) at different doses. Approximately 220 adult participants will be enrolled in the study across 40 sites worldwide.

In part 1, oral ABBV-711 tablets will be given in escalating doses alone to participants with squamous (sq) tumors. In part 2 oral ABBV-711 tablets will be given at a selected dose from part 1 to participants with squamous non-small cell lung cancer (sqNSCLC), or head and neck squamous cell carcinoma (HNSCC). In part 3, oral ABBV-711 tablets will be given in escalating doses in combination with intravenously (IV) infused budigalimab to participants with sq tumors. In part 4 oral ABBV-711 tablets will be given at a selected dose from part 3 in combination with IV infused budigalimab to participants with sqNSCLC, or HNSCC. The estimated duration of the study is up to approximately 5 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent questionnaire, medical assessments, blood tests, and scans.

03

Conditions studied

  • Advanced Squamous Tumors

Keywords

  • Advanced Squamous Tumors
  • ABBV-711
  • ABBV-181
  • Budigalimab
  • Head and Neck Squamous Cell Carcinoma
  • Squamous Non-Small Cell Lung Cancer
  • sqNSCLC
  • HNSCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have progressed on or after standard of care therapy and have no curative therapy available (participants who have refused, are considered ineligible for or are intolerant to standard of care therapy are eligible).
  • Received programmed cell death protein 1 ()/programmed cell death ligand 1 (PD-L1) targeted agents are eligible.
  • Confirmation of available (formalin-fixed paraffin-embedded [FFPE] block or freshly cut slides) or provision of fresh tissue biopsy is required for enrollment in this study for gene expression assessment. If archival tissue requirements cannot be met then the AbbVie therapeutic area Medical Director or designee should be contacted to determine subject eligibility.
  • For head and neck squamous cell carcinoma (HNSCC) participants enrolled in backfill (Part 1 and 3), subjects must provide consent to paired biopsies which are pretreatment and on treatment fresh tumor biopsies from the same tumor lesion, unless deemed not feasible by the investigator where upon consultation with the Sponsor is required. Paired biopsies are encouraged (when safe and feasible) but not required for subjects with squamous non-small cell lung cancer (sqNSCLC) enrolled in the backfill (Part 1 and 3).
  • Evaluable and per (RECIST) Version 1.1.

Exclusion criteria

Exclusion Criteria:

  • Active diseases besides vitiligo, type 1 diabetes, hypothyroidism, hypopituitarism and psoriasis (not requiring systemic treatment); history of primary immunodeficiency, bone marrow transplantation, or solid organ transplantation. Active inflammatory bowel disease unfit for trial in the opinion of the investigator, including subjects requiring systemic therapy with biologics or therapy within the past 2 years.
  • Treatment with any of the following:

    • Anti-cancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any therapy within 28 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of ABBV-711. Palliative radiation therapy for bone, skin or symptomatic with 10 fractions or less is not subject to a .
    • Radiation therapy for central nervous system metastases within 14 days prior to first dose.
  • Subject has systemically used known moderate/strong inhibitors of cytochrome P450 3A (CYP)3A enzyme isoform subfamily within 14 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of study treatment.
  • Has systemically used known moderate/strong inducers of within 14 days prior to the first dose of study treatment.
  • Requires treatment with known moderate or strong inhibitors or inducers of CYP3A from the first dose of study treatment and for the duration of the study.
  • Administration or consumption of any of the following within 3 days prior to first dose of study treatment and while on study treatment: grapefruit or grapefruit products, Seville oranges (including marmaladecontaining Seville oranges), and star fruit.
  • Current or prior use of immunosuppressive medication within 14 days prior to the first dose of the study treatment. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection);
    • Steroids as premedication for reactions (e.g., CT scan premedication);
    • Systemic corticosteroids at doses not to exceed 10 mg/day of prednisone or equivalent.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Part 1: ABBV-711 Monotherapy Dose Escalation

    Participants will receive ABBV-711 in escalating doses alone, as part of the 5 year study duration.

    Drug: ABBV-711

  • Experimental
    Part 2a: ABBV-711 Monotherapy Dose Expansion

    Participants will receive ABBV-711 dose A alone, as part of the 5 year study duration.

    Drug: ABBV-711

  • Experimental
    Part 2b: ABBV-711 Monotherapy Dose Expansion

    Participants will receive ABBV-711 dose B alone, as part of the 5 year study duration.

    Drug: ABBV-711

  • Experimental
    Part 3: ABBV-711 + BudigalimabDose Escalation

    Participants will receive ABBV-711 in escalating doses in combination with budigalimab, as part of the 5 year study duration.

    Drug: ABBV-711 · Drug: Budigalimab

  • Experimental
    Part 4a: ABBV-711 Budigalimab Dose Expansion

    Participants will receive ABBV-711 dose A in combination with budigalimab, as part of the 5 year study duration.

    Drug: ABBV-711 · Drug: Budigalimab

  • Experimental
    Part 4b: ABBV-711 Budigalimab Dose Expansion

    Participants will receive ABBV-711 dose B in combination with budigalimab, as part of the 5 year study duration.

    Drug: ABBV-711 · Drug: Budigalimab

Interventions

  • DrugABBV-711

    Oral Tablet

  • Intravenous Infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AE)s

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately 5 Years

  2. Best overall Response (BOR)

    BOR is defined as partial response (PR) or better per investigator review according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: Up to Approximately 5 Years

Secondary outcomes

  1. Duration of BOR Response

    Duration of response for participants with confirmed PR or better.

    Time frame: Up to Approximately 5 Years

  2. Clinical Benefit Rate (CBR)

    CBR is defined as the percentage of participants with BOR of stable disease (SD) or BOR of PR or better per investigator review according to RECIST version 1.1 criteria.

    Time frame: Up to Approximately 5 Years

  3. Progression-free survival (PFS)

    PFS is defined as time from first ABBV-711 to a documented disease progression according to RECIST version 1.1, as determined by the investigator, or death due to any cause, whichever occurs earlier.

    Time frame: Up to Approximately 5 Years

  4. Duration of response (DOR)

    DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to RECIST 1.1 or other criteria to disease progression or death of any cause, whichever occurs earlier.

    Time frame: Up to Approximately 5 Years

  5. Overall survival (OS)

    OS is defined as time from first ABBV-711 to death due to any cause.

    Time frame: Up to Approximately 5 Years

  6. Area Under the Concentration-Time Curve (AUC) of ABBV-711

    Area under the concentration-time curve of ABBV-711.

    Time frame: Up to Approximately 5 Years

  7. Maximum Observed Concentration (Cmax) of ABBV-711

    Maximum observed concentration of ABBV-711.

    Time frame: Up to Approximately 5 Years

  8. Time to Cmax (Tmax) of ABBV-711

    Time to Cmax of ABBV-711.

    Time frame: Up to Approximately 5 Years

  9. Half-Life (t1/2) of ABBV-711

    Half-life of ABBV-711.

    Time frame: Up to Approximately 5 Years

07

Study locations

13 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Apr 2029, 41 months after the start.

Of 154 industry-sponsored phase 1 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 72. This study's planned 41 months is below that.

Counting every sponsor, half of 270 studies reached it within 49 months; a quarter within 33 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 21, 2025
StartActual
Nov 20, 2025
Primary completionEst.
Apr 2029
CompletionEst.
Oct 2030
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07241039
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Nov 20, 2025
Primary completion
Apr 2029 (estimated)
Completion
Oct 2030 (estimated)
Last update
Aug 19, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion